Novel Treatment Pathways in Pulmonary Arterial Hypertension
By: Kanza N. Qaiser and Adriano R. Tonelli
References
- Galie N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010 Sep; 31(17): 2080–6. doi: 10.1093/eurheartj/ehq152.
- Tonelli AR, Arelli V, Minai OA, et al. Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013 Aug 1; 188(3): 365–9. doi: 10.1164/rccm.201209-1640OC. 2013; 188: 365–9.
- Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012 Aug; 142(2): 448–456. doi: 10.1378/chest.11-1460.
- Hemnes
AR,
Humbert
M. Pathobiology of
pulmonary arterial hypertension: understanding the roads less
travelled. Eur Respir Rev.
2017
Dec
20; 26(146):
170093 . doi: 10.1183/16000617.0093-2017. - Humbert M, Lau EM, Montani D, Jais X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014 Dec 9; 130(24): 2189–208. doi: 10.1161/CIRCULATIONAHA.114.006974.
- Zolty
R. Pulmonary
arterial hypertension specific therapy: The old and the new.
Pharmacol Ther. 2020
Oct; 214:
107576 . doi: 10.1016/j.pharmthera.2020.107576. - Thenappan
T,
Ormiston
ML,
Ryan
JJ,
Archer
SL. Pulmonary
arterial hypertension: pathogenesis and clinical management.
BMJ. 2018
Mar
14; 360:
j5492 . doi: 10.1136/bmj.j5492. - Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med. 2010 Apr; 104(4): 481–96. doi: 10.1016/j.rmed.2009.11.015.
- Tonelli AR, Haserodt S, Aytekin M, Dweik RA. Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy. Pulm Circ. 2013 Jan; 3(1): 20–30. doi: 10.4103/2045-8932.109911.
- Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999 Jun; 159(6): 1925–32. doi: 10.1164/ajrccm.159.6.9804054.
- Falcetti E, Hall SM, Phillips PG, et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010 Nov 1; 182(9): 1161–70. doi: 10.1164/rccm.201001-0011OC.
- Tonelli AR, Zein J, Ioannidis JP. Geometry of the randomized evidence for treatments of pulmonary hypertension. Cardiovasc Ther. 2013 Dec; 31(6): e138–46. doi: 10.1111/1755-5922.12050.
- Galie N, Barbera JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373: 834–44. 2015 Aug 27; 373(9): 834–44. doi: 10.1056/NEJMoa1413687.
- Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25; 369(4): 330–40. doi: 10.1056/NEJMoa1209655.
- Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29; 369(9): 809–18. doi: 10.1056/NEJMoa1213917.
- Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24; 373(26): 2522–33. doi: 10.1056/NEJMoa1503184.
- Galie
N,
Channick
RN,
Frantz
RP, et al. Risk
stratification and medical therapy of pulmonary arterial
hypertension. Eur Respir J.
2019
Jan
24; 53(1):
1801889 . doi: 10.1183/13993003.01889-2018. - Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1; 37(1): 67–119. doi: 10.1093/eurheartj/ehv317.
- Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019 Aug; 156(2): 323–337. doi: 10.1016/j.chest.2019.02.004.
- Hoeper
MM,
Kramer
T,
Pan
Z, et al. Mortality
in pulmonary arterial hypertension: prediction by the 2015 European
pulmonary hypertension guidelines risk stratification model.
Eur Respir J. 2017
Aug
3; 50(2):
1700740 . doi: 10.1183/13993003.00740-2017. - Boucly
A,
Weatherald
J,
Savale
L, et al. Risk
assessment, prognosis and guideline implementation in pulmonary arterial
hypertension. Eur Respir J.
2017
Aug
3; 50(2):
1700889 . doi: 10.1183/13993003.00889-2017. - Macchia A, Marchioli R, Tognoni G, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J. 2010 Feb; 159(2): 245–57. doi: 10.1016/j.ahj.2009.11.028.
- Lajoie AC, Lauziere G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016 Apr; 4(4): 291–305. doi: 10.1016/S2213-2600(16)00027-8.
- Chin
KM,
Sitbon
O,
Doelberg
M, et al. Efficacy
and safety of initial triple oral versus initial double oral combination
therapy in patients with newly diagnosed pulmonary arterial hypertension
(PAH): results of the randomized controlled TRITON study.
Am J Respir Crit Car Med. 2020;
201:
A2928 . - ClinicalTrials.gov [Internet]. Bethesda,
MD: National Library of
Medicine; c2021. Riociguat rEplacing PDE-5i Therapy
evaLuated Against Continued PDE-5i thErapy (REPLACE); 2021 Feb 26 [cited 2021
Apr 12]. Available from:
https://clinicaltrials.gov/ct2/show/NCT02891850 . - Hoeper
MM,
Ghofrani
HA,
Al-Hiti
H, et al. Late
Breaking Abstract – Switching from PDE5i to riociguat in patients with
PAH: The REPLACE study. Eur Resp J.
2020; 56:
A3802 . - ClinicalTrials.gov [Internet]. Bethesda,
MD: National Library of
Medicine; c2021. Outcome Study Assessing a 75 Milligrams
(mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
(UNISUS); 2020 Feb 18 [cited 2021 Apr 12]. Available from:
https://clinicaltrials.gov/ct2/show/NCT04273945 . - ClinicalTrials.gov [Internet]. Bethesda,
MD: National Library of
Medicine; c2021. A Study of GMA301 in Subjects With
Pulmonary Arterial Hypertension; 2020 Aug 7 [cited 2021 Apr 12]. Available from:
https://clinicaltrials.gov/ct2/show/NCT04503733 . - Zhang C, Wang X, Zhang H, et al. Therapeutic Monoclonal Antibody Antagonizing Endothelin Receptor A for Pulmonary Arterial Hypertension. J Pharmacol Exp Ther. 2019 Jul; 370(1): 54–61. doi: 10.1124/jpet.118.252700.
- Torres
F,
Farber
H,
Ristic
A, et al. Efficacy
and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or
dual background therapy: results from a phase 2 randomised, parallel group,
placebo-controlled trial. Eur Respir J.
2019
Oct
10; 54(4):
1901030 . doi: 10.1183/13993003.01030-2019. - ClinicalTrials.gov [Internet]. Bethesda,
MD: National Library of
Medicine; c2021. A Study Evaluating the Efficacy and Safety
of Ralinepag to Improve Treatment Outcomes in PAH Patients; 2018
Aug
13 [cited 2021 Apr 12]. Available from:
https://clinicaltrials.gov/ct2/show/NCT03626688 . - ClinicalTrials.gov [Internet]. Bethesda,
MD: National Library of
Medicine; c2021. A Study of Ralinepag to Evaluate Effects
on Exercise Capacity by CPET in Subjects With WHO Group 1 PH (CAPACITY);
2019
Sep
10 [cited 2021 Apr 12]. Available from:
https://clinicaltrials.gov/ct2/show/NCT04084678 . - Klose
H,
Chin
KM,
Ewert
R, et al. Safety,
Tolerability and Pharmacokinetics Study in Patients with Pulmonary Arterial
Hypertension (PAH) Temporarily Switching from Oral to IV
Selexipag. J Heart Lung Transplant.
2019
Apr
1; 38(4):
S490 . DOI: 10.1016/j.healun.2019.01.1247. - United Therapeutics
[Internet]. Silver Spring, MD:
United Therapeutics Corp.; c2021. United
Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity
Subcutaneous Delivery System for Remodulin®; 2020
Feb
24 [cited 2021 Apr 12]. Available from:
https://ir.unither.com/news/press-releases/press-release-details/2020/United-Therapeutics-and-DEKA-Announce-Additional-FDA-Clearance-Related-to-the-Unity-Subcutaneous-Delivery-System-for-Remodulin/default.aspx . - Bourge RC, Waxman AB, Gomberg-Maitland M, et al. Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial. Chest. 2016 Jul; 150(1): 27–34. doi: 10.1016/j.chest.2015.11.005.
- Feldman J, Habib N, Fann J, Radosevich JJ. Treprostinil in the treatment of pulmonary arterial hypertension. Future Cardiol. 2020 Nov; 16(6): 547–558. doi: 10.2217/fca-2020-0021.
- Shapiro S, Bourge RC, Pozella P, Harris DF, Borg EH, Nelsen AC. Implantable system for treprostinil: a real-world patient experience study. Pulm Circ. 2020 Apr 22; 10(2): 2045894020907881. doi: 10.1177/2045894020907881.
- Orriols M, Gomez-Puerto MC, Ten Dijke P. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Cell Mol Life Sci. 2017 Aug; 74(16): 2979–2995. doi: 10.1007/s00018-017-2510-4.
- Fessel JP, Loyd JE, Austin ED. The genetics of pulmonary arterial hypertension in the post-BMPR2 era. Pulm Circ. Jul-Sep 2011; 1(3): 305–19. doi: 10.4103/2045-8932.87293.
- Larkin EK, Newman JH, Austin ED, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Nov 1; 186(9): 892–6. doi: 10.1164/rccm.201205-0886OC.
- Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002 Apr 9; 105(14): 1672–8. doi: 10.1161/01.cir.0000012754.72951.3d.
- Badesch
D,
Gibbs
S,
Gomberg-Maitland
M, et al. PULSAR: A
phase 2, randomized, double-blind, placebo-controlled study to assess the
efficacy and safety of sotatercept (ACE-011) when added to standard of care
(SOC) for treatment of pulmonary arterial hypertension
(PAH). Eur Respir J. 2019;
54(63):
PA4750 . doi: 10.1183/13993003.congress-2019.PA4750. - Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1; 334(5): 296–301. doi: 10.1056/NEJM199602013340504.
- Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008 Jul 1; 178(1): 81–8. doi: 10.1164/rccm.200707-1037OC.
- ClinicalTrials.gov [Internet]. Bethesda,
MD: National Library of
Medicine; c2021. Imatinib (QTI571) in Pulmonary Arterial
Hypertension (IMPRES); 2009
May
15 [cited 2021 Apr 12]. Available from:
https://clinicaltrials.gov/ct2/show/NCT00902174 . - Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013 Mar 12; 127(10): 1128–38. doi: 10.1161/CIRCULATIONAHA.112.000765.
- Pitsiou G, Zarogoulidis P, Petridis D, et al. Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment. Drug Des Devel Ther. 2014 Oct 7; 8: 1753–63. doi: 10.2147/DDDT.S70277.
- Galkin
A,
Clemons
B,
Garcia
E, et al. Abstract
11102: Gb002, A Novel Inhaled PDGFR Kinase Inhibitor, Demonstrates Efficacy
in the Su5416 Hypoxia Rat Model of Pulmonary Arterial Hypertension
(PAH). Circulation. 2019;
140(Suppl 1):
A11102 . - ClinicalTrials.gov [Internet]. Bethesda,
MD: National Library of
Medicine; c2021. Clinical Study of Inhaled GB002 for
Treatment of WHO Group I Pulmonary Arterial Hypertension (PAH);
2019
Apr 25 15 [cited 2021 Apr 12]. Available from:
https://clinicaltrials.gov/ct2/show/NCT03926793 . - ClinicalTrials.gov [Internet]. Bethesda,
MD: National Library of
Medicine; c2021. GB002 in Adult Subjects With Pulmonary
Arterial Hypertension (PAH); 2020
Jul
7 [cited 2021 Apr 12]. Available from:
https://www.clinicaltrials.gov/ct2/show/NCT04456998 . - Chan
SY,
Rubin
LJ. Metabolic
dysfunction in pulmonary hypertension: from basic science to clinical
practice. Eur Respir Rev. 2017
Dec
20; 26(146):
170094 . doi: 10.1183/16000617.0094-2017. - ClinicalTrials.gov [Internet]. Bethesda,
MD: National Library of
Medicine; c2021.
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) – LARIAT ; 2014 Jan 15 [cited 2021 Apr 12]. Available from:https://www.clinicaltrials.gov/ct2/show/NCT02036970 . - Zhai C, Shi W, Feng W, et al. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation. Life Sci. 2018 Sep 1; 208: 87–95. doi: 10.1016/j.lfs.2018.07.018.
- Oudiz R, Meyer C, Chin M, et al. Initial Data Report from “LARIAT”: A Phase 2 Study of Bardoxolone Methyl in PAH Patients on Stable Background Therapy. Chest. 2015 Oct; 148(4): 639A. doi: 10.1378/chest.2345856.
- ClinicalTrials.gov [Internet]. Bethesda,
MD: National Library of
Medicine; c2021. Extended Access Program to Assess
Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
RANGER (RANGER); 2017
Mar
1 [cited 2021 Apr 12]. Available from:
https://clinicaltrials.gov/ct2/show/NCT03068130l . - ClinicalTrials.gov [Internet]. Bethesda,
MD: National Library of
Medicine; c2021.
Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension – CATALYST ; 2016 Jan 15 [cited 2021 Apr 12]. Available from:https://clinicaltrials.gov/ct2/show/NCT02657356 . - Zamanian RT, Hansmann G, Snook S, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2009 Feb; 33(2): 318–24. doi: 10.1183/09031936.00000508.
- Agard C, Rolli-Derkinderen M, Dumas-de-La-Roque E, et al. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br J Pharmacol. 2009 Nov; 158(5): 1285–94. doi: 10.1111/j.1476-5381.2009.00445.x.
- Dean A, Nilsen M, Loughlin L, Salt IP, MacLean MR. Metformin Reverses Development of Pulmonary Hypertension via Aromatase Inhibition. Hypertension. 2016 Aug; 68(2): 446–54. doi: 10.1161/HYPERTENSIONAHA.116.07353.
- ClinicalTrials.gov [Internet]. Bethesda,
MD: US National Library of
Medicine; c2021.
Hormonal, Metabolic, and Signaling Interactions in PAH ; 2020 Jun 16 [cited 2021 Jun 21]. Available from:https://clinicaltrials.gov/ct2/show/NCT01884051 . - Montani D, Chaumais MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension. 2014 Feb; 141(2): 172–91. doi: 10.1016/j.pharmthera.2013.10.002.
- Hamidi SA, Lin RZ, Szema AM, et al. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension. Respir Res. 2011 Oct 26; 12(1): 141. doi: 10.1186/1465-9921-12-141.
- ClinicalTrials.gov [Internet]. Bethesda,
MD: US National Library of
Medicine; c2021.
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (VIP) ; 2021 Apr 27 [cited 2021 Jun 21]. Available from:https://clinicaltrials.gov/ct2/show/NCT03556020 . - Tofovic SP, Jackson EK. Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension. Int J Mol Sci. 2019 Dec 23; 21(1): 116. doi: 10.3390/ijms21010116.
- ClinicalTrials.gov [Internet]. Bethesda,
MD: US National Library of
Medicine; c2021.
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension (T3PAH) ; 2021 Feb 18 [cited 2021 Jun 21]. Available from:https://clinicaltrials.gov/ct2/show/NCT03528902 . - Kawut SM, Archer-Chicko CL, DeMichele A, et al. Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2017 Feb 1; 195(3): 360–368. doi: 10.1164/rccm.201605-1024OC.
- ClinicalTrials.gov [Internet]. Bethesda,
MD: US National Library of
Medicine; c2021.
Pulmonary Hypertension and Anastrozole Trial (PHANTOM) ; 2020 Aug 3 [cited 2021 Jun 21]. Available from:https://clinicaltrials.gov/ct2/show/NCT03229499 . - Bonnet S, Dumas-de-La-Roque E, Begueret H, et al.: Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci U S A. 2003 Aug 5; 100(16): 9488–93. doi: 10.1073/pnas.1633724100.
- ClinicalTrials.gov [Internet]. Bethesda,
MD: US National Library of
Medicine; c2021.
Effects of DHEA in Pulmonary Hypertension (EDIPHY) ; 2020 Oct 19 [cited 2021 Jun 21]. Available from:https://clinicaltrials.gov/ct2/show/NCT03648385 . - Houssaini A, Abid S, Mouraret N, et al. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol. 2013 May; 48(5): 568–77. doi: 10.1165/rcmb.2012-0429OC.
- ClinicalTrials.gov [Internet]. Bethesda,
MD: US National Library of
Medicine; c2021.
ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension ; 2021 Feb 18 [cited 2021 Jun 21]. Available from:https://clinicaltrials.gov/ct2/show/NCT02587325 .
DOI: https://doi.org/10.14797/CBHS2234 | Journal eISSN: 1947-6108
Language: English
Page range: 29 - 37
Accepted on: Nov 18, 2020
Published on: Jul 1, 2021
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
© 2021 Kanza N. Qaiser, Adriano R. Tonelli, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.